RUNX1T1

Last update 23 Jan 2025

Basic Info

Synonyms

AML1T1, CBFA2T1, CDR

+ [11]

Introduction

Transcriptional corepressor which facilitates transcriptional repression via its association with DNA-binding transcription factors and recruitment of other corepressors and histone-modifying enzymes (PubMed:12559562, PubMed:15203199, PubMed:10688654). Can repress the expression of MMP7 in a ZBTB33-dependent manner (PubMed:23251453). Can repress transactivation mediated by TCF12 (PubMed:16803958). Acts as a negative regulator of adipogenesis (By similarity). The AML1-MTG8/ETO fusion protein frequently found in leukemic cells is involved in leukemogenesis and contributes to hematopoietic stem/progenitor cell self-renewal (PubMed:23812588).

100 Clinical Results associated with RUNX1T1

100 Translational Medicine associated with RUNX1T1

0 Patents (Medical) associated with RUNX1T1

1,187

Literatures (Medical) associated with RUNX1T1

01 Mar 2025·Biochemistry and Biophysics Reports

Investigating combined hypoxia and stemness indices for prognostic transcripts in gastric cancer: Machine learning and network analysis approaches

Article

Author: Nikpour, Parvaneh ; Lotfi-Shahreza, Maryam ; Mahmoudian-Hamedani, Sharareh

IntroductionGastric cancer (GC) is among the deadliest malignancies globally, characterized by hypoxia-driven pathways that promote cancer progression, including stemness mechanisms facilitating invasion and metastasis. This study aimed to develop a prognostic decision tree using genes implicated in hypoxia and stemness pathways to predict outcomes in GC patients.Materials and methodsGC RNA-seq data from The Cancer Genome Atlas (TCGA) were analyzed to compute hypoxia and stemness scores using Gene Set Variation Analysis (GSVA) and the mRNA expression-based stemness index (mRNAsi). Hierarchical clustering identified clusters with distinct survival outcomes, and differentially expressed genes (DEGs) between clusters were identified. Weighted Gene Co-expression Network Analysis (WGCNA) identified modules and hub genes associated with clinical traits. Overlapping DEGs and hub genes underwent functional enrichment, protein-protein interaction (PPI) network analysis, and survival analysis. A prognostic decision tree was constructed using survival-associated shared genes.ResultsHierarchical clustering identified six clusters among 375 TCGA GC patients, with significant survival differences between cluster 1 (low hypoxia, high stemness) and cluster 4 (high hypoxia, high stemness). Validation in the GSE62254 dataset corroborated these findings. WGCNA revealed modules linked to clinical traits and survival, with functional enrichment highlighting pathways like cell adhesion and calcium signaling. The decision tree, based on genes such as AKAP6, GLRB, and RUNX1T1, achieved an AUC of 0.81 (training) and 0.67 (test), demonstrating the utility of combined scores in patient stratification.ConclusionThis study introduces a novel hypoxia-stemness-based prognostic decision tree for GC. The identified genes show promise as prognostic biomarkers, warranting further clinical validation.

01 Mar 2025·International Journal of Biological Macromolecules

Genome-wide analysis reveals porcine LIFR regulated by DNA methylation promotes the implantation process via the STAT3 signaling

Article

Author: Zhou, Changfan ; Pius, Lenox ; Huang, Shuntao ; Liu, Min ; Xu, Dequan ; Zheng, Shuailong

Embryo-uterine interaction during embryo implantation depends on the coordinated expression of numerous genes in the receptive endometrium. While DNA methylation is known to play a significant role in controlling gene expression, specific molecular mechanisms underlying this regulatory event remain elusive in early porcine pregnancy. Here, we investigated the genome-wide DNA methylation landscape in the Yorkshire and Meishan pig's endometrium. The results revealed a higher degree of DNA methylation modifications on gene promoter regions on day 32 of pregnancy compared to that on day 18 of pregnancy. By integrating the mRNA and methylation profiles, leukemia inhibitory factor receptor (LIFR) was identified as a differentially methylated and expressed gene, crucial in early pregnancy. LIFR expression is epigenetically silenced via promoter hypermethylation from days 18 to 32 of pregnancy. Moreover, functional assays demonstrated that LIFR knockdown inhibited the proliferation, adhesion, and migration of endometrial epithelial cells (EECs) and downregulated the expression of STAT3 signaling and pregnancy-related genes. In vivo studies further revealed a reduction of implanted mouse embryos upon loss of function of LIFR. Furthermore, RUNX1 up-regulates LIFR expression by binding to the differentially methylated region (DMR) of the LIFR promoter. High levels of RUNX1T1, in turn, recruit RUNX1/HDAC1/DNMTs to assemble a regulatory complex that silences LIFR expression through the same locus. Collectively, our findings shed light on the role of dynamic DNA methylation and the epigenetic regulation of LIFR on embryo implantation in early swine pregnancy.

01 Feb 2025·American Journal of Hematology

Efficacy of Midostaurin Combined With Intensive Chemotherapy in Core Binding Factor Leukemia: A Phase II Clinical Trial

Article

Author: Basilico, Claudia ; Ubezio, Marta ; Stefanucci, Marta Rachele ; Borlenghi, Erika ; Greco, Rosa ; Brando, Bruno ; Zappasodi, Patrizia ; Fumagalli, Monica ; Mancini, Valentina ; Veronese, Silvio Marco ; Nadali, Gianpaolo ; Krampera, Mauro ; Molteni, Alfredo ; Bernardi, Massimo ; Todisco, Elisabetta ; Grillo, Giovanni ; Di Camillo, Barbara ; Gatti, Arianna ; Beghini, Alessandro ; Turrini, Mauro ; Riva, Marta ; Bernasconi, Davide Paolo ; Cairoli, Roberto

Samples from 34 adult patients newly diagnosed with core binding factor leukemia (CBFL) were collected both at the time of diagnosis and at relapse and were centrally analyzed. Eligible patients received either standard induction CT known as "3 + 7" or an equivalent regimen, according to the recruiting center's policy. Patients who achieved CR or CRi received 3 courses of high-dose ARA-C (Cytarabine) 3000 mg/m² every 12 h on days 1, 3, and 5, along with midostaurin at the dose of 50 mg b.i.d from Day 8 to Day 21 as part of consolidation therapy. Following the completion of the consolidation phase, patients received midostaurin as a monotherapy at the dose of 50 mg b.i.d. for 1 year as continuation therapy. The CR rate was 97%; we recorded an OS rate of 73.52% and a DFS rate of 48.4% for the entire cohort. The RI was 38.8% in the CBFB::MYH11 and 66.6% in the RUNX1::RUNX1T1 group. MRD (Measurable Residual Disease) was assessed by RQ-PCR at 10 time points throughout the study, as indicated by arrows.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

RUNX1T1

Basic Info

Related

Analysis